A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted therapies for MTC, including the selective RET inhibitors selpercatinib and pralsetinib, have led to changes in the management of patients with locally advanced, metastatic, or recurrent MTC. In this article, we review updates on the evaluation and management of patients with MTC, focusing on new and emerging therapies that are likely to improve patient outcomes.

• Publication year

  2023

• Venue

  Surgical Oncology Clinics of North America

• Publication date

  2023-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.soc.2022.10.002PMID 36925182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medullary Thyroid Cancer with Ectopic Cushing's Syndrome: A Case Report and Systematic Review of Detailed Cases from the Literature

  2022cited by this paper
• Inclusion of the Number of Metastatic Lymph Nodes in the Staging System for Medullary Thyroid Cancer: Validating a Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System

  2022cited by this paper
• Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

  2021cited by this paper
• The importance of the RET gene in thyroid cancer and therapeutic implications

  2021cited by this paper
• Exceptionality of Distant Metastases in Node-Negative Hereditary and Sporadic Medullary Thyroid Cancer: Lessons Learned.

  2021cited by this paper
• Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia

  2021cited by this paper
• Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy

  2021cited by this paper
• Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series

  2021cited by this paper
• International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma

  2021cited by this paper
• Geographical Variation in the profile of RET Variants in Patients with Medullary Thyroid Cancer: A Comprehensive Review.

  2021cited by this paper
• The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.

  2020cited by this paper
• Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

  2020cited by this paper
• Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors

  2020cited by this paper
• Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?

  2020cited by this paper
• Neoadjuvant selpercatinib for advanced medullary thyroid cancer

  2020cited by this paper
• Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy

  2020cited by this paper
• Association between age and disease specific mortality in medullary thyroid cancer.

  2020cited by this paper
• Selpercatinib Aimed at RET-Altered Cancers.

  2020cited by this paper
• Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

  2020cited by this paper
• Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies

  2020cited by this paper
• Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis.

  2020cited by this paper
• Comprehensive Immune Profiling of Medullary Thyroid Cancer

  2020cited by this paper
• Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies

  2020cited by this paper
• Advances in Targeting RET-Dependent Cancers.

  2020cited by this paper
• State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

  2020cited by this paper
• Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma

  2020cited by this paper
• The Diagnostic Value of Ultrasound in Medullary Thyroid Carcinoma: A Comparison With Computed Tomography

  2020cited by this paper
• TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

  2019cited by this paper
• EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

  2019cited by this paper
• The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review.

  2019cited by this paper
• The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review

  2019cited by this paper
• Time to calcitonin normalization after surgery for node‐negative and node‐positive medullary thyroid cancer

  2019cited by this paper
• A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

  2019cited by this paper
• CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma

  2019cited by this paper
• Medullary thyroid carcinoma: Application of Thyroid Imaging Reporting and Data System (TI-RADS) Classification

  2018cited by this paper
• Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.

  2018cited by this paper
• Barriers to the recognition of medullary thyroid carcinoma on FNA: Implications relevant to the new American Thyroid Association guidelines

  2018cited by this paper
• Long‐term outcome of prophylactic thyroidectomy in children carrying RET germline mutations

  2018cited by this paper
• Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer

  2017cited by this paper
• Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

  2017cited by this paper
• Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

  2017cited by this paper
• Complications of Bilateral Neck Dissection in Thyroid Cancer From a Single High-Volume Center

  2017cited by this paper
• A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

  2017cited by this paper
• The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values

  2017cited by this paper
• New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis

  2016cited by this paper
• A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma

  2016cited by this paper
• RAS proto-oncogene in medullary thyroid carcinoma.

  2015cited by this paper
• Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

  2015cited by this paper
• A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

  2015cited by this paper
• Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort

  2015cited by this paper
• Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer

  2015cited by this paper
• Guidelines for the management of thyroid cancer

  2014cited by this paper
• The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer.

  2014cited by this paper
• Update on the Cytologic and Molecular Features of Medullary Thyroid Carcinoma

  2014cited by this paper
• Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study.

  2014cited by this paper
• Prognostic Impact of N Staging in 715 Medullary Thyroid Cancer Patients: Proposal for a Revised Staging System

  2013cited by this paper
• Cabozantinib in progressive medullary thyroid cancer.

  2013cited by this paper
• Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report.

  2013cited by this paper
• Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

  2012cited by this paper
• Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.

  2012cited by this paper
• Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Metastatic Medullary Thyroid Cancer Presenting with Elevated Levels of CA 19-9 and CA 125

  2011cited by this paper
• High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

  2011cited by this paper
• Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

  2010cited by this paper
• Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

  2010cited by this paper
• Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.

  2010cited by this paper
• Phase II trial of sunitinib in medullary thyroid cancer (MTC).

  2010cited by this paper
• Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.

  2009cited by this paper
• Clinical and economic outcomes of thyroid and parathyroid surgery in children.

  2008cited by this paper
• Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma

  2008cited by this paper
• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

  2007cited by this paper
• Chemoembolization for liver metastases from medullary thyroid carcinoma.

  2006cited by this paper
• Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

  2005cited by this paper
• Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

  2005cited by this paper
• Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma.

  2005cited by this paper
• Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

  2005cited by this paper
• Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

  2004cited by this paper
• Early malignant progression of hereditary medullary thyroid cancer.

  2003cited by this paper
• Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination

  2002cited by this paper
• The Role of Radiotherapy in the Management of Elevated Calcitonin After Surgery for Medullary Thyroid Cancer

  2001cited by this paper
• Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.

  2001cited by this paper
• Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer.

  2000cited by this paper
• Medullary thyroid carcinoma

  2000cited by this paper
• Normal Thyroid Pathology in Patients Undergoing Thyroidectomy for Finding a RETgene Germline Mutation: A Report of Three Cases and Review of the Literature

  1999cited by this paper
• Medullary Thyroid Cancer: Analyses of Survival and Prognostic Factors and the Role of Radiation Therapy in Local Control

  1996cited by this paper
• Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

  1995cited by this paper
• Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine

  1995cited by this paper
• Loss of function effect of RET mutations causing Hirschsprung disease

  1995cited by this paper
• Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

  1994cited by this paper
• Blood group antigen expression in medullary carcinoma of the thyroid

  1992cited by this paper
• Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

  1990cited by this paper
• Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma

  1984cited by this paper
• Medullary Carcinoma of the Thyroid: A STUDY OF THE CLINICAL FEATURES AND PROGNOSTIC FACTORS IN 161 PATIENTS

  1984cited by this paper

• Recent Advances in the Diagnostics and Management of Medullary Thyroid Carcinoma: Emphasis on Biomarkers and Thyroidectomy in Neuroendocrine Neoplasms

  2024cites this paper
• Quality of outcome reporting for clinical trails on medullary thyroid cancer registered on ClinicalTrials.gov.

  2023cites this paper
• Advances in Diagnostics and Therapy of Medullary Thyroid Carcinoma (MTC)– A Mini-Review

  2023cites this paper